PSI (TFA)-Get quote

Description

PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas[1].—COVID-19-anti-virus–C34H51F3N4O10—-[1] Saji C, et al. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells. Biochem Biophys Res Commun. 2011; 415(4):573-8.—-732.78—-OC(C(F)(F)F)=O.O=C([C@H]([C@@H](C)CC)NC(OCC1=CC=CC=C1)=O)N[C@@H](CCC(OC(C)(C)C)=O)C(N[C@@H](C)C(N[C@H](C=O)CC(C)C)=O)=O–Cancer; Infection–10 mM in DMSO–Proteasome—-Metabolic Enzyme/Protease–Peptides